Journal of Clinical Oncology, Vol 16, 3601-3606, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Prognostic factors in the treatment of human immunodeficiency virus- associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases

DJ Straus, J Huang, MA Testa, AM Levine and LD Kaplan
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. strausd@mskcc.org

PURPOSE: The overall results of chemotherapy in human immunodeficiency virus (HIV)-associated non-Hodgkin's lymphoma (NHL) have been poor. To define a subgroup of patients who may have a better outcome, an analysis of prognostic factors was performed of patients treated in AIDS Clinical Trials Group (ACTG) protocol 142, a phase III randomized trial of low-dose versus standard-dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of patients with newly diagnosed HIV-associated NHL. MATERIALS AND METHODS: The following baseline variables were included as potential predictors of survival among 192 patients who received treatment: age; intravenous drug use (IVDU); specific type of sexual contact as risk factors (homosexual, bisexual, or heterosexual contact); prior AIDS diagnosis; CD4 cell count; serum lactic acid dehydrogenase (LDH); histology; Karnofsky performance status (KPS); stage; B symptoms; race (white/nonwhite); nodal involvement; extranodal involvement; number of extranodal sites; specific sites: bone marrow, liver, kidney, lung, or gastrointestinal tract; and treatment arm (standard-dose m-BACOD/low-dose m-BACOD). RESULTS: Age greater than 35 years, IVDU, stages III/IV, and CD4 cell counts less than 100/microL were adverse prognostic factors in multivariate analyses using the Cox proportional hazards model. The median overall survival for patients with none or one of the adverse factors was 46 weeks, with two was 44 weeks, and with three or four was 18 weeks. At 144 weeks, 29.5% of patients with none or one, 16.9% with two, and 0% with three or four factors were alive (P < .001). CONCLUSION: Long-term survival can be achieved in approximately one third of patients with HIV-associated NHL with favorable characteristics.

This article has been cited by other articles:

				V. Subbiah, O.W. Mwanda, J. Orem, P. Fu, C. Banura, J. Kakembo, A. Ness, J. Johnson, J. Bako, E. Katongole-Mbidde, et al. Analyses of Prognostic Factors for Survival in East African Patients with AIDS-Related Non-Hodgkin's Lymphoma (AR-NHL) Treated with Dose Modified Oral Chemotherapy. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 3862 - 3862. [Abstract] [PDF]

				F. Boue, J. Gabarre, C. Gisselbrecht, J. Reynes, A. Cheret, F. Bonnet, E. Billaud, M. Raphael, R. Lancar, and D. Costagliola Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma J. Clin. Oncol., September 1, 2006; 24(25): 4123 - 4128. [Abstract] [Full Text] [PDF]

				S. Combs, N. Neil, and D. M. Aboulafia Liposomal Doxorubicin, Cyclophosphamide, and Etoposide and Antiretroviral Therapy for Patients with AIDS-Related Lymphoma: A Pilot Study. Oncologist, June 1, 2006; 11(6): 666 - 673. [Abstract] [Full Text] [PDF]

				N. Mounier, M. Spina, J. Gabarre, M. Raphael, G. Rizzardini, J.-B. Golfier, E. Vaccher, A. Carbone, B. Coiffier, G. Chichino, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy Blood, May 15, 2006; 107(10): 3832 - 3840. [Abstract] [Full Text] [PDF]

				S.-T. Lim, R. Karim, A. Tulpule, B. N. Nathwani, and A. M. Levine Prognostic Factors in HIV-Related Diffuse Large-Cell Lymphoma: Before Versus After Highly Active Antiretroviral Therapy J. Clin. Oncol., November 20, 2005; 23(33): 8477 - 8482. [Abstract] [Full Text] [PDF]

				L. D. Kaplan, J. Y. Lee, R. F. Ambinder, J. A. Sparano, E. Cesarman, A. Chadburn, A. M. Levine, and D. T. Scadden Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010 Blood, September 1, 2005; 106(5): 1538 - 1543. [Abstract] [Full Text] [PDF]

				C. Hoffmann, M. Tiemann, C. Schrader, D. Janssen, E. Wolf, M. Vierbuchen, R. Parwaresch, K. Ernestus, A. Plettenberg, A. Stoehr, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping Blood, September 1, 2005; 106(5): 1762 - 1769. [Abstract] [Full Text] [PDF]

				S. T. Lim, R. Karim, B. N. Nathwani, A. Tulpule, B. Espina, and A. M. Levine AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre-Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard Chemotherapy J. Clin. Oncol., July 1, 2005; 23(19): 4430 - 4438. [Abstract] [Full Text] [PDF]

				M. C. Cheung, L. Pantanowitz, and B. J. Dezube AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy Oncologist, June 1, 2005; 10(6): 412 - 426. [Abstract] [Full Text] [PDF]

				G. Tisdale, A. Mahadevan, and R. H. Matthews T-Cell Lymphoma of the Rectum in a Patient with AIDS and Hepatitis C: A Case Report and Discussion Oncologist, April 1, 2005; 10(4): 292 - 298. [Abstract] [Full Text] [PDF]

				M. Spina, U. Jaeger, J. A. Sparano, R. Talamini, C. Simonelli, M. Michieli, G. Rossi, E. Nigra, M. Berretta, C. Cattaneo, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials Blood, March 1, 2005; 105(5): 1891 - 1897. [Abstract] [Full Text] [PDF]

				J. A. Sparano, S. Lee, M. G. Chen, T. Nazeer, A. Einzig, R. F. Ambinder, D. H. Henry, J. Manalo, T. Li, and J. H. Von Roenn Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkin's Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494) J. Clin. Oncol., April 15, 2004; 22(8): 1491 - 1500. [Abstract] [Full Text] [PDF]

				T. Powles, M. Bower, G. Daugaard, J. Shamash, A. De Ruiter, M. Johnson, M. Fisher, J. Anderson, S. Mandalia, J. Stebbing, et al. Multicenter Study of Human Immunodeficiency Virus-Related Germ Cell Tumors J. Clin. Oncol., May 15, 2003; 21(10): 1922 - 1927. [Abstract] [Full Text] [PDF]

				P. A. Volberding, K. R. Baker, and A. M. Levine Human Immunodeficiency Virus Hematology Hematology, January 1, 2003; 2003(1): 294 - 313. [Abstract] [Full Text] [PDF]

				M. W. Otieno, C. Banura, E. Katongole-Mbidde, J. L. Johnson, M. Ghannoum, A. Dowlati, R. Renne, E. Arts, C. Whalen, M. M. Lederman, et al. Therapeutic Challenges of AIDS-Related Non-Hodgkin's Lymphoma in the United States and East Africa J Natl Cancer Inst, May 15, 2002; 94(10): 718 - 732. [Abstract] [Full Text] [PDF]

				S. Alas, C.-P. Ng, and B. Bonavida Rituximab Modifies the Cisplatin-mitochondrial Signaling Pathway, Resulting in Apoptosis in Cisplatin-resistant Non-Hodgkin's Lymphoma Clin. Cancer Res., March 1, 2002; 8(3): 836 - 845. [Abstract] [Full Text] [PDF]

				L. Seneviratne, B. M. Espina, B. N. Nathwani, J. A. Chan, R. K. Brynes, and A. M. Levine Clinical, immunologic, and pathologic correlates of bone marrow involvement in 291 patients with acquired immunodeficiency syndrome-related lymphoma Blood, October 15, 2001; 98(8): 2358 - 2363. [Abstract] [Full Text] [PDF]

				L. Ratner, J. Lee, S. Tang, D. Redden, F. Hamzeh, B. Herndier, D. Scadden, L. Kaplan, R. Ambinder, A. Levine, et al. Chemotherapy for Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma in Combination With Highly Active Antiretroviral Therapy J. Clin. Oncol., April 15, 2001; 19(8): 2171 - 2178. [Abstract] [Full Text] [PDF]

				A. M. Levine, L. Seneviratne, B. M. Espina, A. R. Wohl, A. Tulpule, B. N. Nathwani, and P. S. Gill Evolving characteristics of AIDS-related lymphoma Blood, December 15, 2000; 96(13): 4084 - 4090. [Abstract] [Full Text] [PDF]

				G. V. Matthews, M. Bower, S. Mandalia, T. Powles, M. R. Nelson, and B. G. Gazzard Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy Blood, October 15, 2000; 96(8): 2730 - 2734. [Abstract] [Full Text] [PDF]

				T. Powles, G. Matthews, and M. Bower AIDS related systemic non-Hodgkin's lymphoma Sex Transm Inf, October 1, 2000; 76(5): 335 - 341. [Abstract] [Full Text] [PDF]

				B. U. Mueller Cancers in Children Infected With the Human Immunodeficiency Virus Oncologist, August 1, 1999; 4(4): 309 - 317. [Abstract] [Full Text]